273 related articles for article (PubMed ID: 31534628)
1. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
Huang MB; Wu JY; Lillard J; Bond VC
Oncotarget; 2019 Sep; 10(52):5419-5438. PubMed ID: 31534628
[No Abstract] [Full Text] [Related]
2. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells.
Huang MB; Gonzalez RR; Lillard J; Bond VC
Oncotarget; 2017 Feb; 8(7):11302-11315. PubMed ID: 28076321
[TBL] [Abstract][Full Text] [Related]
3. Novel secretion modification region (SMR) peptide exhibits anti-metastatic properties in human breast cancer cells.
Huang MB; Brena D; Wu JY; Roth WW; Owusu S; Bond VC
Sci Rep; 2022 Aug; 12(1):13204. PubMed ID: 35915218
[TBL] [Abstract][Full Text] [Related]
4. Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release.
Shelton MN; Huang MB; Ali SA; Powell MD; Bond VC
J Virol; 2012 Jan; 86(1):406-19. PubMed ID: 22013042
[TBL] [Abstract][Full Text] [Related]
5. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
6. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
7. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
8. Peptide-based identification of functional motifs and their binding partners.
Shelton MN; Huang MB; Ali S; Johnson K; Roth W; Powell M; Bond V
J Vis Exp; 2013 Jun; (76):. PubMed ID: 23852082
[TBL] [Abstract][Full Text] [Related]
9. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
11. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
13. Novel role of mortalin in attenuating HIV-1 Tat-mediated astrogliosis.
Priyanka ; Wadhwa R; Chaudhuri R; Nag TC; Seth P
J Neuroinflammation; 2020 Sep; 17(1):276. PubMed ID: 32951595
[TBL] [Abstract][Full Text] [Related]
14. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis.
Na Y; Kaul SC; Ryu J; Lee JS; Ahn HM; Kaul Z; Kalra RS; Li L; Widodo N; Yun CO; Wadhwa R
Cancer Res; 2016 May; 76(9):2754-2765. PubMed ID: 26960973
[TBL] [Abstract][Full Text] [Related]
15. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway.
Hu Y; Yang L; Yang Y; Han Y; Wang Y; Liu W; Zuo J
J Cell Mol Med; 2016 Nov; 20(11):2111-2121. PubMed ID: 27374312
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast.
Jin H; Ji M; Chen L; Liu Q; Che S; Xu M; Lin Z
J Exp Clin Cancer Res; 2016 Mar; 35():42. PubMed ID: 26955804
[TBL] [Abstract][Full Text] [Related]
19. Mortalin promotes cell proliferation and epithelial mesenchymal transition of intrahepatic cholangiocarcinoma cells in vitro.
Kang Q; Cai JB; Dong RZ; Liu LX; Zhang C; Zhang PF; Zou H; Xie N; Zhang L; Zhang XY; Song ZJ; Dong ZR; Hu MY; Huang XY; Zhang XW; Ke AW; Shi GM
J Clin Pathol; 2017 Aug; 70(8):677-683. PubMed ID: 28096273
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
